本研究旨在确定影响使用生物或靶向合成缓解病情抗风湿药物 (b/tsDMARD) 治疗的类风湿关节炎患者膝关节症状缓解的因素。在 2010 年至 2023 年间开始 b/tsDMARD 的 2321 名患者中，我们重点关注了 295 名在开始 b/tsDMARD 时出现膝部肿胀或压痛并持续 b/tsDMARD 至少 3 个月的患者，并在 6 个月后记录了膝部症状。 6 个月后，白细胞介素 6 (IL-6) 抑制剂的症状缓解率为 78.2%，Janus 激酶 (JAK) 抑制剂为 68.6%，肿瘤坏死因子 (TNF) 抑制剂为 65.8%，细胞毒性 T 淋巴细胞相关抗原为 57.6%。 4-Ig (CTLA4-Ig)。与 CTLA4-Ig 相比，b/tsDMARD 的初始使用和 IL-6 抑制剂的使用成为与膝关节症状改善相关的重要因素。在基线时和两年后接受膝关节X光检查的141名患者中，IL-6抑制剂的膝关节X光片恶化率为7.7%，JAK抑制剂为6.3%，TNF抑制剂为21.9%，CTLA4-Ig为25.9%。与 CTLA4-Ig 相比，IL-6 抑制剂的使用是改善膝关节症状和抑制关节破坏的重要因素。© 2024。作者。

This study aims to identify factors influencing the alleviation of knee joint symptoms in patients with rheumatoid arthritis treated with biologic or target synthetic disease-modifying antirheumatic drugs (b/tsDMARDs). Among 2321 patients who started b/tsDMARDs between 2010 and 2023, we focused on 295 patients who had knee swelling or tenderness at the initiation of b/tsDMARDs and continued b/tsDMARDs at least 3 months, with recorded knee symptoms 6 months later. Symptom relief after 6 months was 78.2% for interleukin 6 (IL-6) inhibitors, 68.6% for Janus kinase (JAK) inhibitors, 65.8% for tumor necrosis factor (TNF) inhibitors, and 57.6% for cytotoxic T lymphocyte-associated antigen-4-Ig (CTLA4-Ig). The initial use of b/tsDMARDs and the use of IL-6 inhibitors in comparison to CTLA4-Ig emerged as a significant factor associated with the improvement of knee joint symptoms. Among 141 patients who underwent knee radiography at baseline and two years later, the deterioration in knee joint radiographs was 7.7% for IL-6 inhibitors, 6.3% for JAK inhibitors, 21.9% for TNF inhibitors, and 25.9% for CTLA4-Ig. The use of IL-6 inhibitors was a significant factor associated with the improvement of knee joint symptoms and the inhibition of joint destruction compared to CTLA4-Ig.© 2024. The Author(s).